Acute toxicity and effects on hepatic oxidative drug metabolism of mopyridone.

Abstract

Mopyridone (CAS 82822-14-8) is a new chemotherapeutic with a strong antiviral effect (vs. influenza- and toga viruses) and certain advantages over the chemotherapeutics known so far. Toxicological studies reveal its low oral and intraperitoneal toxicity in mice and rats. The 5- and 14-day administration of mopyridone (37.5 mg/kg b.w., orally) to male rats established a growing tendency to the shortening of hexobarbital sleeping time, associated with moderate changes in the hepatic oxidase activity on the 15th day, most pronounced for amidopyrine N-demethylase (by 37%) and less for benzphetamine N-demethylase (by 17%). Aniline hydroxylase activity was slightly diminished (by 18% and 16%, resp.). No significant changes in the components of the electron-transport chain of cytochrome P-450 were established--the content of cytochrome P-450, cytochrome b-5 and cytochrome C reductase, both after 5- and 14-day mopyridone administration.

• Authors: L Tantcheva, A S Galabov, M Behar, D Sidzhakova
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 44 Issue 3 Pg. 354-7 (Mar 1994) ISSN: 0004-4172 [Print] Germany
• PMID: 8192702 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Pharmaceutical Preparations
• Pyrimidinones
• Hexobarbital
• 1-morpholinomethyl-tetrahydro-1(1H)-pyrimidinone
• Mixed Function Oxygenases

Topics

• Animals
• Antiviral Agents (pharmacology, toxicity)
• Female
• Hexobarbital (pharmacology)
• Lethal Dose 50
• Liver (drug effects, enzymology, metabolism)
• Male
• Mice
• Microsomes, Liver (drug effects, enzymology)
• Mixed Function Oxygenases (metabolism)
• Oxidation-Reduction
• Pharmaceutical Preparations (metabolism)
• Pyrimidinones (pharmacology, toxicity)
• Rats
• Rats, Wistar
• Sleep (drug effects)